Please wait while the formulary information is being retrieved.
DRUG IMAGES
- No Image Available
The following indications for ANTI-ITCH (hydrocortisone) have been approved by the FDA:
Indications:
Allergic dermatitis
Atopic dermatitis
Contact dermatitis
Cutaneous T-cell lymphoma
Discoid lupus erythematosus
Genital organ pruritus
Granuloma annulare
Lichen simplex chronicus
Plaque psoriasis
Pruritus ani
Pruritus of skin
Pyoderma gangrenosum
Scalp psoriasis
Seborrheic dermatitis
Skin inflammation
Skin irritation
Professional Synonyms:
Atopic eczema
Circumscribed neurodermatitis
Dermatitis seborrheica
Dermatitis venenata
Dermatitis
Disseminated neurodermatitis
Dyssebacea
Dyssebacia
Genital pruritus
Itchy skin eruption
Lichen annularis
Primary cutaneous T-cell lymphoma
Pruritic dermatitis
Seborrhea corporis
Seborrheic eczema
Small cerebriform cell lymphoma
Unna's disease
Vidal's disease
Indications:
Allergic dermatitis
Atopic dermatitis
Contact dermatitis
Cutaneous T-cell lymphoma
Discoid lupus erythematosus
Genital organ pruritus
Granuloma annulare
Lichen simplex chronicus
Plaque psoriasis
Pruritus ani
Pruritus of skin
Pyoderma gangrenosum
Scalp psoriasis
Seborrheic dermatitis
Skin inflammation
Skin irritation
Professional Synonyms:
Atopic eczema
Circumscribed neurodermatitis
Dermatitis seborrheica
Dermatitis venenata
Dermatitis
Disseminated neurodermatitis
Dyssebacea
Dyssebacia
Genital pruritus
Itchy skin eruption
Lichen annularis
Primary cutaneous T-cell lymphoma
Pruritic dermatitis
Seborrhea corporis
Seborrheic eczema
Small cerebriform cell lymphoma
Unna's disease
Vidal's disease
The following dosing information is available for ANTI-ITCH (hydrocortisone):
Hydrocortisone and its acetate, buteprate, butyrate, and valerate esters are applied topically. Dermatologic preparations of the drugs are applied sparingly in thin films and are rubbed gently into the affected area 1-4 times daily. Rectal creams and ointments of the drugs are applied externally to the anal area.
Some commercially available creams may be applied externally to the anogenital areas. Nonprescription preparations of the drugs should not be used for self-medication for longer than 7 days; if the condition worsens or symptoms persist, the drug should be discontinued and a physician consulted. Nonprescription preparations of the drugs should not be used in children younger than 2 years of age unless directed and supervised by a physician.
For dermatoses of the scalp, the hair may be parted and a small amount of lotion applied directly to the affected area and rubbed gently into the scalp. Usual hair care should be maintained, but the lotion should not be washed out immediately after application. Alternatively, for dermatoses of the scalp, hydrocortisone aerosol is applied to the dry scalp after shampooing.
When the aerosol is used for other dermatoses, each 10-cm2 of affected area is sprayed for 1-2 seconds from a distance of about 15 cm 2 or 3 times daily.
Occlusive dressings may be used for severe or resistant dermatoses.
For use in the mouth, a small amount of 0.5% hydrocortisone acetate paste is pressed to the lesion without rubbing until a thin film develops. The paste is applied 2 or 3 times daily after meals and at bedtime.
If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.
Hydrocortisone is administered rectally as a retention enema, and hydrocortisone acetate is given rectally as a suppository or an aerosol foam suspension according to the manufacturers' instructions. Patients should be advised that hydrocortisone acetate suppositories may stain fabric so that they can take appropriate precautionary measures. For the adjunctive treatment of ulcerative colitis, 100 mg of hydrocortisone is administered nightly as a retention enema.
The patient should lie on his left side during and for 30 minutes after administration of the retention enema so that the drug will distribute throughout the left colon; the enema should be retained for at least 1 hour and preferably all night. Some clinicians administer 100 mg as a retention enema twice daily followed by 100 mg nightly when improvement occurs. The drug is usually given for 21 days or until clinical and proctologic remissions are achieved.
Clinical symptoms may improve in 3-5 days, followed by proctologic improvement; in some cases, 2-3 months of therapy may be required to attain a proctologic remission. Therapy with hydrocortisone retention enema should be discontinued if clinical or proctologic improvement does not occur within 2-3 weeks. Following treatment for longer than 21 days, therapy with hydrocortisone enema should be withdrawn gradually by giving the drug every other night for 2-3 weeks and then discontinuing it.
In patients with ulcerative proctitis of the distal rectum who cannot retain corticosteroid enemas, 90 mg of hydrocortisone acetate (1 applicatorful of a 10% aerosol foam suspension) may be given rectally 1 or 2 times daily for 2-3 weeks and then, if necessary, every other day until clinical and proctologic improvements occur; symptoms may improve within 5-7 days. For the adjunctive treatment of ulcerative colitis of the rectum and other inflammatory conditions of the anorectum, 25 mg of hydrocortisone acetate as a suppository may be administered rectally in the morning and at night for 2 weeks; in severe proctitis, 25 mg may be given 3 times daily or 50 mg may be given twice daily. For the adjunctive treatment of postirradiation or factitial proctitis, therapy is generally continued for 6-8 weeks or less if an adequate response is attained.
Alternatively, for the symptomatic treatment of internal hemorrhoids and the adjunctive treatment of other inflammatory conditions of the anorectum, 10 mg of hydrocortisone acetate as a suppository may be administered rectally in the morning and at night for 2-6 days.
Dosage should be individualized according to the patient's response and tolerance.
The usual adult oral dosage of diphenhydramine hydrochloride is 25-50 mg 3 or 4 times daily at 4- to 6-hour intervals, not to exceed 300 mg in 24 hours.
The usual adult IM or IV dose of diphenhydramine hydrochloride is 10-50 mg; in a few patients, up to 100 mg may be required. Some experts recommend a dose of 25-50 mg. The rate of IV administration should not exceed 25 mg/minute.
The maximum adult IM or IV dosage of diphenhydramine hydrochloride is 400 mg daily.
When diphenhydramine was available only by prescription, the prescribing information for the drug indicated a usual oral diphenhydramine hydrochloride dosage for children weighing more than 9.1 kg of 12.5-25 mg 3 or 4 times daily at 4- to 6-hour intervals and for children weighing 9.1
kg or less an oral diphenhydramine hydrochloride dosage of 6.25-12.5 mg 3 or 4 times daily at 4- to 6-hour intervals.
However, these dosage recommendations are not included in the current labeling of nonprescription oral diphenhydramine preparations, and clinicians should use caution when considering use of nonprescription oral diphenhydramine in children younger than 4 years of age. (See Cautions: Pediatric Precautions.)
Alternatively, for oral, deep IM, or IV therapy, children (other than premature or full-term neonates) may be given 5 mg/kg daily or 150 mg/m2 daily divided in 4 doses; some experts recommend a dosage of 1-2 mg/kg daily. The rate of IV administration should not exceed 25 mg/minute.
The maximum oral, IM, or IV dosage of diphenhydramine hydrochloride in children older than 1 month of age is 300 mg daily.
For temporary relief of pruritus and pain associated with various skin conditions in adults and children 2 years of age or older, creams, lotions, or solutions containing 1-2% diphenhydramine hydrochloride are applied to the affected areas 3 or 4 times daily or as directed by a clinician; topical diphenhydramine should not be used more often than directed.
If the condition worsens, or if symptoms persist for longer than 7 days or resolve and then recur within a few days, topical therapy with diphenhydramine hydrochloride should be discontinued and a clinician consulted; the possibility of sensitization by, or hypersensitivity to, the drug should be considered.
Topical preparations containing diphenhydramine hydrochloride should not be used on large areas of the body or concomitantly with other preparations containing the antihistamine, including those used orally, since increased serum concentrations of diphenhydramine may occur that can result in systemic toxicity. (See Acute Toxicity: Manifestations, in the Antihistamines General Statement 4:00.) The drug also should not be used for topical self-medication in the management of varicella (chickenpox) or measles without first consulting a clinician.
Some commercially available creams may be applied externally to the anogenital areas. Nonprescription preparations of the drugs should not be used for self-medication for longer than 7 days; if the condition worsens or symptoms persist, the drug should be discontinued and a physician consulted. Nonprescription preparations of the drugs should not be used in children younger than 2 years of age unless directed and supervised by a physician.
For dermatoses of the scalp, the hair may be parted and a small amount of lotion applied directly to the affected area and rubbed gently into the scalp. Usual hair care should be maintained, but the lotion should not be washed out immediately after application. Alternatively, for dermatoses of the scalp, hydrocortisone aerosol is applied to the dry scalp after shampooing.
When the aerosol is used for other dermatoses, each 10-cm2 of affected area is sprayed for 1-2 seconds from a distance of about 15 cm 2 or 3 times daily.
Occlusive dressings may be used for severe or resistant dermatoses.
For use in the mouth, a small amount of 0.5% hydrocortisone acetate paste is pressed to the lesion without rubbing until a thin film develops. The paste is applied 2 or 3 times daily after meals and at bedtime.
If substantial regeneration or repair of the oral tissues does not occur after 7 days of treatment, further investigation of the etiology of the oral lesions should be undertaken.
Hydrocortisone is administered rectally as a retention enema, and hydrocortisone acetate is given rectally as a suppository or an aerosol foam suspension according to the manufacturers' instructions. Patients should be advised that hydrocortisone acetate suppositories may stain fabric so that they can take appropriate precautionary measures. For the adjunctive treatment of ulcerative colitis, 100 mg of hydrocortisone is administered nightly as a retention enema.
The patient should lie on his left side during and for 30 minutes after administration of the retention enema so that the drug will distribute throughout the left colon; the enema should be retained for at least 1 hour and preferably all night. Some clinicians administer 100 mg as a retention enema twice daily followed by 100 mg nightly when improvement occurs. The drug is usually given for 21 days or until clinical and proctologic remissions are achieved.
Clinical symptoms may improve in 3-5 days, followed by proctologic improvement; in some cases, 2-3 months of therapy may be required to attain a proctologic remission. Therapy with hydrocortisone retention enema should be discontinued if clinical or proctologic improvement does not occur within 2-3 weeks. Following treatment for longer than 21 days, therapy with hydrocortisone enema should be withdrawn gradually by giving the drug every other night for 2-3 weeks and then discontinuing it.
In patients with ulcerative proctitis of the distal rectum who cannot retain corticosteroid enemas, 90 mg of hydrocortisone acetate (1 applicatorful of a 10% aerosol foam suspension) may be given rectally 1 or 2 times daily for 2-3 weeks and then, if necessary, every other day until clinical and proctologic improvements occur; symptoms may improve within 5-7 days. For the adjunctive treatment of ulcerative colitis of the rectum and other inflammatory conditions of the anorectum, 25 mg of hydrocortisone acetate as a suppository may be administered rectally in the morning and at night for 2 weeks; in severe proctitis, 25 mg may be given 3 times daily or 50 mg may be given twice daily. For the adjunctive treatment of postirradiation or factitial proctitis, therapy is generally continued for 6-8 weeks or less if an adequate response is attained.
Alternatively, for the symptomatic treatment of internal hemorrhoids and the adjunctive treatment of other inflammatory conditions of the anorectum, 10 mg of hydrocortisone acetate as a suppository may be administered rectally in the morning and at night for 2-6 days.
Dosage should be individualized according to the patient's response and tolerance.
The usual adult oral dosage of diphenhydramine hydrochloride is 25-50 mg 3 or 4 times daily at 4- to 6-hour intervals, not to exceed 300 mg in 24 hours.
The usual adult IM or IV dose of diphenhydramine hydrochloride is 10-50 mg; in a few patients, up to 100 mg may be required. Some experts recommend a dose of 25-50 mg. The rate of IV administration should not exceed 25 mg/minute.
The maximum adult IM or IV dosage of diphenhydramine hydrochloride is 400 mg daily.
When diphenhydramine was available only by prescription, the prescribing information for the drug indicated a usual oral diphenhydramine hydrochloride dosage for children weighing more than 9.1 kg of 12.5-25 mg 3 or 4 times daily at 4- to 6-hour intervals and for children weighing 9.1
kg or less an oral diphenhydramine hydrochloride dosage of 6.25-12.5 mg 3 or 4 times daily at 4- to 6-hour intervals.
However, these dosage recommendations are not included in the current labeling of nonprescription oral diphenhydramine preparations, and clinicians should use caution when considering use of nonprescription oral diphenhydramine in children younger than 4 years of age. (See Cautions: Pediatric Precautions.)
Alternatively, for oral, deep IM, or IV therapy, children (other than premature or full-term neonates) may be given 5 mg/kg daily or 150 mg/m2 daily divided in 4 doses; some experts recommend a dosage of 1-2 mg/kg daily. The rate of IV administration should not exceed 25 mg/minute.
The maximum oral, IM, or IV dosage of diphenhydramine hydrochloride in children older than 1 month of age is 300 mg daily.
For temporary relief of pruritus and pain associated with various skin conditions in adults and children 2 years of age or older, creams, lotions, or solutions containing 1-2% diphenhydramine hydrochloride are applied to the affected areas 3 or 4 times daily or as directed by a clinician; topical diphenhydramine should not be used more often than directed.
If the condition worsens, or if symptoms persist for longer than 7 days or resolve and then recur within a few days, topical therapy with diphenhydramine hydrochloride should be discontinued and a clinician consulted; the possibility of sensitization by, or hypersensitivity to, the drug should be considered.
Topical preparations containing diphenhydramine hydrochloride should not be used on large areas of the body or concomitantly with other preparations containing the antihistamine, including those used orally, since increased serum concentrations of diphenhydramine may occur that can result in systemic toxicity. (See Acute Toxicity: Manifestations, in the Antihistamines General Statement 4:00.) The drug also should not be used for topical self-medication in the management of varicella (chickenpox) or measles without first consulting a clinician.
Diphenhydramine hydrochloride usually is administered orally. Diphenhydramine citrate usually is administered orally. When oral therapy is not feasible, diphenhydramine hydrochloride may be given by deep IM or, preferably, IV injection.
The drug should not be given subcutaneously, intradermally, or perivascularly because of its irritating effects; local necrosis has been reported following subcutaneous or intradermal administration of parenteral diphenhydramine. IV use of the drug in a home-care setting should be employed under careful supervision. Use of diphenhydramine for local anesthesia via local infiltration is discouraged because of the risk of local tissue necrosis.
Diphenhydramine hydrochloride should not be given to premature or full-term neonates. (See Cautions: Pediatric Precautions.) For the temporary relief of pruritus associated with various skin conditions and disorders, diphenhydramine hydrochloride-containing preparations are applied topically in the form of a cream, lotion, or topical solution. The possibility of clinically important percutaneous absorption of the drug following topical application should be considered. (See Cautions.)
The drug should not be given subcutaneously, intradermally, or perivascularly because of its irritating effects; local necrosis has been reported following subcutaneous or intradermal administration of parenteral diphenhydramine. IV use of the drug in a home-care setting should be employed under careful supervision. Use of diphenhydramine for local anesthesia via local infiltration is discouraged because of the risk of local tissue necrosis.
Diphenhydramine hydrochloride should not be given to premature or full-term neonates. (See Cautions: Pediatric Precautions.) For the temporary relief of pruritus associated with various skin conditions and disorders, diphenhydramine hydrochloride-containing preparations are applied topically in the form of a cream, lotion, or topical solution. The possibility of clinically important percutaneous absorption of the drug following topical application should be considered. (See Cautions.)
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ANTI-ITCH (hydrocortisone):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ANTI-ITCH (hydrocortisone):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
Hypothalamic-pituitary insufficiency |
No disease contraindications |
The following adverse reaction information is available for ANTI-ITCH (hydrocortisone):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 15 severe adverse reactions.
More Frequent | Less Frequent |
---|---|
None. |
Folliculitis Purpura Skin and skin structure infection Skin atrophy |
Rare/Very Rare |
---|
Adrenocortical insufficiency Bullous dermatitis Cataracts Central serous chorioretinopathy Glaucoma Hypothalamic-pituitary insufficiency Ocular hypertension Skin hypopigmentation Skin striae Skin ulcer Urticaria |
There are 24 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Erythema Stinging of skin |
Folliculitis Purpura Skin and skin structure infection Skin atrophy |
Rare/Very Rare |
---|
Acneiform eruption Alopecia Blistering skin Contact dermatitis Dry skin Dyschromia Glycosuria Hirsutism Hypercortisolism Hyperesthesia Hyperglycemia Miliaria Perioral dermatitis Skin irritation |
The following precautions are available for ANTI-ITCH (hydrocortisone):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Management or Monitoring Precaution
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
Diphenhydramine (topical) | 1 Day – 2 Years | Consult clinician prior to use age < 2 years. |
Management or Monitoring Precaution
Hydrocortisone (Top,Ophth,Rect) | 1 Day – 18 Years | Prolonged or extensive use may lead to systemic absorption; may affect growth rate. |
Reproduction studies in rats and rabbits receiving diphenhydramine hydrochloride dosages up to 5 times the recommended human dosage have not revealed evidence of harm to the fetus. However, diphenhydramine has been shown to cross the placenta. In one epidemiologic study, use of bromodiphenhydramine (no longer commercially available) but not diphenhydramine was associated with an increased risk of teratogenic effects.
In another epidemiologic study, there also was no evidence of increased risk of teratogenicity associated with diphenhydramine use during the first trimester, although a modest association could not be ruled out. Use of diphenhydramine during the first trimester of pregnancy has been associated with an increased risk of cleft palate alone or combined with other fetal abnormalities, and the drug has been reported to potentiate the teratogenic effect of morphine in mice. The manufacturers state that there are no adequate and controlled studies to date using diphenhydramine in pregnant women, and the drugs should be used during pregnancy only when clearly needed.
In another epidemiologic study, there also was no evidence of increased risk of teratogenicity associated with diphenhydramine use during the first trimester, although a modest association could not be ruled out. Use of diphenhydramine during the first trimester of pregnancy has been associated with an increased risk of cleft palate alone or combined with other fetal abnormalities, and the drug has been reported to potentiate the teratogenic effect of morphine in mice. The manufacturers state that there are no adequate and controlled studies to date using diphenhydramine in pregnant women, and the drugs should be used during pregnancy only when clearly needed.
Drug/Drug Class | Severity | Precaution Description | Pregnancy Category Description |
---|---|---|---|
Hydrocortisone (topical, Non-systemic) | 2 | Insufficient human data available | No fda rating but may have precautions or warnings; may have animal and/or human studies or pre or post marketing information. |
Diphenhydramine | B | Animal studies have failed to demonstrate a risk to the fetus but there are no well-controlled studies in pregnant women; or animal reproduction studies have shown an adverse effect (other than decrease in fertility), but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of a risk in later trimesters). |
Diphenhydramine has been detected in milk. Because of the potential for serious adverse reactions to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or diphenhydramine, taking into account the importance of the drug to the woman.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
No Known Risk
No known risk. This drug has no known risks to nursing infants and does not adversely affect lactation.
Precaution Exists
Precaution exists. (No data or inconclusive human data.) Use of this drug by breast feeding mothers should be evaluated carefully.
Drug Name | Excretion Potential | Effect on Infant | Notes |
---|---|---|---|
Diphenhydramine | Excreted.This drug is known to be excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Limited data suggest increased drowsiness, and irritability |
No Known Risk
No known risk. This drug has no known risks to nursing infants and does not adversely affect lactation.
Drug Name | Excretion Potential | Effect on Infant | Notes |
---|---|---|---|
Hydrocortisone (top., Rectal) | Unknown. It is unknown whether the drug is excreted in human breast milk. | It is not known whether this drug has an adverse effect on the nursing infant. (No data or inconclusive human data) | Insufficient data available; limited use may pose little risk |
No enhanced Geriatric Use information available for this drug.
Precaution Exists
Geriatric management or monitoring precaution exists.
Precaution Exists
Geriatric management or monitoring precaution exists.
Drug Name | Narrative | REN | HEP | CARDIO | NEURO | PULM | ENDO |
---|---|---|---|---|---|---|---|
Diphenhydramine | Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Maximum of 25mg/day. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause. | N | N | N | Y | N | N |
The following prioritized warning is available for ANTI-ITCH (hydrocortisone):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ANTI-ITCH (hydrocortisone)'s list of indications:
Allergic dermatitis | |
L20 | Atopic dermatitis |
L20.0 | Besnier's prurigo |
L20.8 | Other atopic dermatitis |
L20.81 | Atopic neurodermatitis |
L20.82 | Flexural eczema |
L20.83 | Infantile (acute) (chronic) eczema |
L20.84 | Intrinsic (allergic) eczema |
L20.89 | Other atopic dermatitis |
L20.9 | Atopic dermatitis, unspecified |
L23 | Allergic contact dermatitis |
L23.0 | Allergic contact dermatitis due to metals |
L23.1 | Allergic contact dermatitis due to adhesives |
L23.2 | Allergic contact dermatitis due to cosmetics |
L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
L23.4 | Allergic contact dermatitis due to dyes |
L23.5 | Allergic contact dermatitis due to other chemical products |
L23.6 | Allergic contact dermatitis due to food in contact with the skin |
L23.7 | Allergic contact dermatitis due to plants, except food |
L23.8 | Allergic contact dermatitis due to other agents |
L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
L23.89 | Allergic contact dermatitis due to other agents |
L23.9 | Allergic contact dermatitis, unspecified cause |
Atopic dermatitis | |
L20 | Atopic dermatitis |
L20.0 | Besnier's prurigo |
L20.8 | Other atopic dermatitis |
L20.81 | Atopic neurodermatitis |
L20.82 | Flexural eczema |
L20.84 | Intrinsic (allergic) eczema |
L20.89 | Other atopic dermatitis |
L20.9 | Atopic dermatitis, unspecified |
Contact dermatitis | |
L23 | Allergic contact dermatitis |
L23.0 | Allergic contact dermatitis due to metals |
L23.1 | Allergic contact dermatitis due to adhesives |
L23.2 | Allergic contact dermatitis due to cosmetics |
L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
L23.4 | Allergic contact dermatitis due to dyes |
L23.5 | Allergic contact dermatitis due to other chemical products |
L23.6 | Allergic contact dermatitis due to food in contact with the skin |
L23.7 | Allergic contact dermatitis due to plants, except food |
L23.8 | Allergic contact dermatitis due to other agents |
L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
L23.89 | Allergic contact dermatitis due to other agents |
L23.9 | Allergic contact dermatitis, unspecified cause |
L24 | Irritant contact dermatitis |
L24.0 | Irritant contact dermatitis due to detergents |
L24.1 | Irritant contact dermatitis due to oils and greases |
L24.2 | Irritant contact dermatitis due to solvents |
L24.3 | Irritant contact dermatitis due to cosmetics |
L24.4 | Irritant contact dermatitis due to drugs in contact with skin |
L24.5 | Irritant contact dermatitis due to other chemical products |
L24.6 | Irritant contact dermatitis due to food in contact with skin |
L24.7 | Irritant contact dermatitis due to plants, except food |
L24.8 | Irritant contact dermatitis due to other agents |
L24.81 | Irritant contact dermatitis due to metals |
L24.89 | Irritant contact dermatitis due to other agents |
L24.9 | Irritant contact dermatitis, unspecified cause |
L24.A0 | Irritant contact dermatitis due to friction or contact with body fluids, unspecified |
L24.A1 | Irritant contact dermatitis due to saliva |
L24.A2 | Irritant contact dermatitis due to fecal, urinary or dual incontinence |
L24.A9 | Irritant contact dermatitis due friction or contact with other specified body fluids |
L24.B | Irritant contact dermatitis related to stoma or fistula |
L24.B0 | Irritant contact dermatitis related to unspecified stoma or fistula |
L24.B1 | Irritant contact dermatitis related to digestive stoma or fistula |
L24.B2 | Irritant contact dermatitis related to respiratory stoma or fistula |
L24.B3 | Irritant contact dermatitis related to fecal or urinary stoma or fistula |
L25 | Unspecified contact dermatitis |
L25.0 | Unspecified contact dermatitis due to cosmetics |
L25.1 | Unspecified contact dermatitis due to drugs in contact with skin |
L25.2 | Unspecified contact dermatitis due to dyes |
L25.3 | Unspecified contact dermatitis due to other chemical products |
L25.4 | Unspecified contact dermatitis due to food in contact with skin |
L25.5 | Unspecified contact dermatitis due to plants, except food |
L25.8 | Unspecified contact dermatitis due to other agents |
L25.9 | Unspecified contact dermatitis, unspecified cause |
Cutaneous t-cell lymphoma | |
C84.0 | Mycosis fungoides |
C84.A | Cutaneous t-cell lymphoma, unspecified |
C84.A0 | Cutaneous t-cell lymphoma, unspecified, unspecified site |
C84.A1 | Cutaneous t-cell lymphoma, unspecified lymph nodes of head, face, and neck |
C84.A2 | Cutaneous t-cell lymphoma, unspecified, intrathoracic lymph nodes |
C84.A3 | Cutaneous t-cell lymphoma, unspecified, intra-abdominal lymph nodes |
C84.A4 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of axilla and upper limb |
C84.A5 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
C84.A6 | Cutaneous t-cell lymphoma, unspecified, intrapelvic lymph nodes |
C84.A7 | Cutaneous t-cell lymphoma, unspecified, spleen |
C84.A8 | Cutaneous t-cell lymphoma, unspecified, lymph nodes of multiple sites |
C84.A9 | Cutaneous t-cell lymphoma, unspecified, extranodal and solid organ sites |
Discoid lupus erythematosus | |
H01.12 | Discoid lupus erythematosus of eyelid |
H01.121 | Discoid lupus erythematosus of right upper eyelid |
H01.122 | Discoid lupus erythematosus of right lower eyelid |
H01.123 | Discoid lupus erythematosus of right eye, unspecified eyelid |
H01.124 | Discoid lupus erythematosus of left upper eyelid |
H01.125 | Discoid lupus erythematosus of left lower eyelid |
H01.126 | Discoid lupus erythematosus of left eye, unspecified eyelid |
H01.129 | Discoid lupus erythematosus of unspecified eye, unspecified eyelid |
L93.0 | Discoid lupus erythematosus |
Genital organ pruritus | |
L29.2 | Pruritus vulvae |
L29.3 | Anogenital pruritus, unspecified |
Granuloma annulare | |
L92.0 | Granuloma annulare |
Lichen simplex chronicus | |
L28.0 | Lichen simplex chronicus |
Plaque psoriasis | |
L40.0 | Psoriasis vulgaris |
L40.9 | Psoriasis, unspecified |
Pruritus ani | |
L29.0 | Pruritus ani |
L29.3 | Anogenital pruritus, unspecified |
Pruritus of skin | |
L29.8 | Other pruritus |
L29.81 | Cholestatic pruritus |
L29.89 | Other pruritus |
L29.9 | Pruritus, unspecified |
Pyoderma gangrenosum | |
L88 | Pyoderma gangrenosum |
Scalp psoriasis | |
L40.0 | Psoriasis vulgaris |
L40.1 | Generalized pustular psoriasis |
L40.4 | Guttate psoriasis |
L40.8 | Other psoriasis |
L40.9 | Psoriasis, unspecified |
Seborrheic dermatitis | |
L21 | Seborrheic dermatitis |
L21.0 | Seborrhea capitis |
L21.1 | Seborrheic infantile dermatitis |
L21.8 | Other seborrheic dermatitis |
L21.9 | Seborrheic dermatitis, unspecified |
Skin inflammation | |
L20 | Atopic dermatitis |
L20.8 | Other atopic dermatitis |
L20.89 | Other atopic dermatitis |
L20.9 | Atopic dermatitis, unspecified |
L21 | Seborrheic dermatitis |
L21.8 | Other seborrheic dermatitis |
L21.9 | Seborrheic dermatitis, unspecified |
L25 | Unspecified contact dermatitis |
L30.8 | Other specified dermatitis |
L30.9 | Dermatitis, unspecified |
L40 | Psoriasis |
L40.1 | Generalized pustular psoriasis |
L40.8 | Other psoriasis |
L40.9 | Psoriasis, unspecified |
R21 | Rash and other nonspecific skin eruption |
Skin irritation | |
L24 | Irritant contact dermatitis |
L24.0 | Irritant contact dermatitis due to detergents |
L24.1 | Irritant contact dermatitis due to oils and greases |
L24.2 | Irritant contact dermatitis due to solvents |
L24.3 | Irritant contact dermatitis due to cosmetics |
L24.4 | Irritant contact dermatitis due to drugs in contact with skin |
L24.5 | Irritant contact dermatitis due to other chemical products |
L24.6 | Irritant contact dermatitis due to food in contact with skin |
L24.7 | Irritant contact dermatitis due to plants, except food |
L24.8 | Irritant contact dermatitis due to other agents |
L24.81 | Irritant contact dermatitis due to metals |
L24.89 | Irritant contact dermatitis due to other agents |
L24.9 | Irritant contact dermatitis, unspecified cause |
L24.A | Irritant contact dermatitis due to friction or contact with body fluids |
L24.A0 | Irritant contact dermatitis due to friction or contact with body fluids, unspecified |
L24.A1 | Irritant contact dermatitis due to saliva |
L24.A2 | Irritant contact dermatitis due to fecal, urinary or dual incontinence |
L24.A9 | Irritant contact dermatitis due friction or contact with other specified body fluids |
L24.B | Irritant contact dermatitis related to stoma or fistula |
L24.B0 | Irritant contact dermatitis related to unspecified stoma or fistula |
L24.B1 | Irritant contact dermatitis related to digestive stoma or fistula |
L24.B2 | Irritant contact dermatitis related to respiratory stoma or fistula |
L24.B3 | Irritant contact dermatitis related to fecal or urinary stoma or fistula |
L25 | Unspecified contact dermatitis |
L25.0 | Unspecified contact dermatitis due to cosmetics |
L25.1 | Unspecified contact dermatitis due to drugs in contact with skin |
L25.2 | Unspecified contact dermatitis due to dyes |
L25.3 | Unspecified contact dermatitis due to other chemical products |
L25.4 | Unspecified contact dermatitis due to food in contact with skin |
L25.5 | Unspecified contact dermatitis due to plants, except food |
L25.8 | Unspecified contact dermatitis due to other agents |
L25.9 | Unspecified contact dermatitis, unspecified cause |
L30.9 | Dermatitis, unspecified |
R21 | Rash and other nonspecific skin eruption |
Formulary Reference Tool